Substantia Nigra

• 

  Subject Areas on Research

  • 6-Hydroxydopamine injections into the nigrostriatal pathway attenuate striatal malonate and 3-nitropropionic acid lesions. 
  • A Neural Circuit for Gut-Induced Reward. 
  • Abrogation of α-synuclein-mediated dopaminergic neurodegeneration in LRRK2-deficient rats. 
  • Activation of substantia nigra neurons: role in the propagation of seizures in kindled rats. 
  • Activation of substantia nigra pars reticulata neurons: role in the initiation and behavioral expression of kindled seizures. 
  • Activity of neurons in monkey globus pallidus during oculomotor behavior compared with that in substantia nigra pars reticulata. 
  • Acute and chronic nicotinic interactions with dopamine systems and working memory performance. 
  • Alterations in baseline activity and quinpirole sensitivity in putative dopamine neurons in the substantia nigra and ventral tegmental area after withdrawal from cocaine pretreatment. 
  • Altered activity of midbrain dopamine neurons following 7-day withdrawal from chronic cocaine abuse is normalized by D2 receptor stimulation during the early withdrawal phase. 
  • Altered sensitivity of dopamine autoreceptors in rat accumbens 1 and 7 days after intermittent or continuous cocaine withdrawal. 
  • Anatomy of disturbed sleep in pallido-ponto-nigral degeneration. 
  • Androgen decreases dopamine neurone survival in rat midbrain. 
  • Anticonvulsant action of intranigral gamma-vinyl-GABA: role of nonadrenergic neurotransmission. 
  • Augmented methamphetamine-induced overflow of striatal dopamine 1 day after GDNF administration. 
  • Autophagy protects against aminochrome-induced cell death in substantia nigra-derived cell line. 
  • Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. 
  • Bidirectional modulation of substantia nigra activity by motivational state. 
  • Biochemical and behavioral evaluation of pergolide as a dopamine agonist in the rat brain. 
  • CHEMICAL STIMULATION OF RED NUCLEUS, SUBSTANTIA NIGRA, AND BASIS PEDUNCULI IN ALERT CATS. 
  • Central acoustic tract in an echolocating bat: an extralemniscal auditory pathway to the thalamus. 
  • Changes in dynorphin, enkephalin and cholecystokinin content of hippocampus and substantia nigra after amygdala kindling. 
  • Characterization of the axon initial segment of mice substantia nigra dopaminergic neurons. 
  • Chronic cocaine administration increases CNS tyrosine hydroxylase enzyme activity and mRNA levels and tryptophan hydroxylase enzyme activity levels. 
  • Chronic lithium administration has no effect on haloperidol-induced supersensitivity of pre- and postsynaptic dopamine receptors in rat brain. 
  • Clomiphene blocks the effect of intravenous estradiol on the firing rate of rat nigral dopamine neurons. 
  • Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. 
  • Colocalization of excitatory and inhibitory neurotransmitter markers in striatal projection neurons in the rat. 
  • Combined treatment with acupuncture reduces effective dose and alleviates adverse effect of L-dopa by normalizing Parkinson's disease-induced neurochemical imbalance. 
  • Creatine and cyclocreatine attenuate MPTP neurotoxicity. 
  • Deprenyl treatment attenuates long-term pre- and post-synaptic changes evoked by chronic methamphetamine. 
  • Detailed analysis of estrous-related changes in wheel running and self-stimulation. 
  • Diagnostic Accuracy of Transcranial Sonography of the Substantia Nigra in Parkinson's disease: A Systematic Review and Meta-analysis. 
  • Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents. 
  • Differential effects of SCH 23390 on the apomorphine subsensitivity in the substantia nigra and ventral tegmental area 1 day following withdrawal from continuous or intermittent cocaine pretreatment. 
  • Differential expression of the B'beta regulatory subunit of protein phosphatase 2A modulates tyrosine hydroxylase phosphorylation and catecholamine synthesis. 
  • Differential response of ventral midbrain and striatal progenitor cells to lesions of the nigrostriatal dopaminergic projection. 
  • Does dopamine contribute to striatal damage caused by impaired mitochondrial function? 
  • Dopamine and α-synuclein dysfunction in Smad3 null mice. 
  • Dopamine receptors status after unilateral nigral 6-OHDA lesion. Autoradiographic and in situ hybridization study in the rat brain. 
  • Dopamine: burning the candle at both ends. 
  • Dual control of dopamine synthesis and release by presynaptic and postsynaptic dopamine D2 receptors. 
  • Effect of continuous systemic infusion of D-amphetamine on the sensitivity of nigral dopamine cells to apomorphine inhibition of firing rates. 
  • Effects of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-induced hemiparkinsonism on the kinematics of a two-dimensional,multijoint arm movement in the rhesus monkey. 
  • Effects of intranigral application of clinically-effective anticonvulsants on electroshock-induced seizures. 
  • Evidence implicating alpha-2 adrenergic receptors in the anticonvulsant action of intranigral muscimol. 
  • Evidence implicating substantia nigra in regulation of kindled seizure threshold. 
  • Evidence that Substantia Nigra is crucial to neural network of kindled seizures. 
  • Exploring the role of the substantia nigra pars reticulata in eye movements. 
  • Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. 
  • Extraocular muscle dystonia due to acquired (non-Wilsonian) hepatocerebral degeneration. 
  • Fast serotonin voltammetry as a versatile tool for mapping dynamic tissue architecture: I. Responses at carbon fibers describe local tissue physiology. 
  • Functional association of the parkin gene promoter with idiopathic Parkinson's disease. 
  • GDNF protection against 6-OHDA-induced reductions in potassium-evoked overflow of striatal dopamine. 
  • Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. 
  • Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues. 
  • Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra. 
  • Genomic convergence: identifying candidate genes for Parkinson's disease by combining serial analysis of gene expression and genetic linkage. 
  • Identification and quantification of dolichol and dolichoic acid in neuromelanin from substantia nigra of the human brain. 
  • Identification of a novel gene linked to parkin via a bi-directional promoter. 
  • In vitro extracellular recording from nigral dopamine neurons following continuous d-amphetamine infusion. 
  • Induction of c-fos mRNA by kindled seizures: complex relationship with neuronal burst firing. 
  • Influence of regional iron on the motor impairments of Parkinson's disease: A quantitative susceptibility mapping study. 
  • Interactions of nigrostriate synaptic transmission, iontophoretic O-methylated phenethylamines, dopamine, apomorphine and acetylcholine. 
  • Interhemispheric modulation of dopamine receptor interactions in unilateral 6-OHDA rodent model. 
  • Intracellular recording from dopamine neurons in the substantia nigra: double labelling for identification of projection site and morphological features. 
  • Intranigral administration of D2 dopamine receptor antisense oligodeoxynucleotides establishes a role for nigrostriatal D2 autoreceptors in the motor actions of cocaine. 
  • Intranigral dynorphin-1-13 suppresses kindled seizures by a naloxone-insensitive mechanism. 
  • Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease. 
  • Kindling model of epilepsy. 
  • Kindling: an animal model of complex partial epilepsy. 
  • LC/MS analysis of cardiolipins in substantia nigra and plasma of rotenone-treated rats: Implication for mitochondrial dysfunction in Parkinson's disease. 
  • Lesioning of the striatum reverses motor asymmetry in the 6-hydroxydopamine rodent model of parkinsonism. 
  • Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration. 
  • Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. 
  • Luminopsins integrate opto- and chemogenetics by using physical and biological light sources for opsin activation. 
  • MR microscopy at 7.0 T: effects of brain iron. 
  • MRI of brain iron. 
  • Mechanisms of action selection and timing in substantia nigra neurons. 
  • Medical treatment of Parkinson disease. 
  • Microinjection of a benzodiazepine into substantia nigra elevates kindled seizure threshold. 
  • Mitochondrial DNA damage: molecular marker of vulnerable nigral neurons in Parkinson's disease. 
  • Mitochondrial DNA deletions/rearrangements in parkinson disease and related neurodegenerative disorders. 
  • Morphometry of the human substantia nigra in ageing and Parkinson's disease. 
  • Motivated behavior and the estrous cycle in rats. 
  • Neurobiochemical changes in tardive dyskinesia. 
  • Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease. 
  • Neurological disturbances, nigrostriate synapses, and iontophoretic dopamine and apomorphine after haloperidol. 
  • Neurotensin-induced dopamine release in vivo and in vitro from substantia nigra and nucleus caudate. 
  • Nigrostriatal bundle damage and the lateral hypothalamic syndrome. 
  • Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. 
  • Oestrogen receptors enhance dopamine neurone survival in rat midbrain. 
  • Operant self-stimulation of dopamine neurons in the substantia nigra. 
  • Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity. 
  • Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron. 
  • Quantitative 1H magnetic resonance spectroscopic imaging determines therapeutic immunization efficacy in an animal model of Parkinson's disease. 
  • Region-specific disturbed iron distribution in early idiopathic Parkinson's disease measured by quantitative susceptibility mapping. 
  • Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. 
  • Relationships between the nigrotectal pathway and the cells of origin of the predorsal bundle. 
  • Relative contributions of local cell and passing fiber activation and silencing to changes in thalamic fidelity during deep brain stimulation and lesioning: a computational modeling study. 
  • Resting state networks distinguish human ventral tegmental area from substantia nigra. 
  • Role of the substantia nigra in the kindling model of limbic epilepsy. 
  • Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. 
  • Single-cell redox imaging demonstrates a distinctive response of dopaminergic neurons to oxidative insults. 
  • Stimulation of substantia nigra pars reticulata enhances dentate granule cell excitability. 
  • Striatonigral control of movement velocity in mice. 
  • Substantia nigra activity level predicts trial-to-trial adjustments in cognitive control. 
  • Susceptibility-enhanced 3-Tesla T1-weighted spoiled gradient echo of the midbrain nuclei for guidance of deep brain stimulation implantation. 
  • Synapsins differentially control dopamine and serotonin release. 
  • Synthesis and dopamine agonist properties of (+-)-trans-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano [4,3-b]-1,4-oxazin-9-ol and its enantiomers. 
  • Targeted deletion of GD3 synthase protects against MPTP-induced neurodegeneration. 
  • The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins. 
  • The effects of chronic bromocriptine treatment on behaviour and dopamine receptor binding in the rat striatum. 
  • The nigral projection to predorsal bundle cells in the superior colliculus of the rat. 
  • The nigrotectal projection in the cat: an electron microscope autoradiographic study. 
  • The progressive changes of neuronal activities of the nigral dopaminergic neurons upon withdrawal from continuous infusion of cocaine. 
  • The role of substantia nigra in the development of kindling: pharmacologic and lesion studies. 
  • The role of the substantia nigra in posture control. 
  • The sources of the nigrotectal pathway. 
  • The surface oxidation potential of human neuromelanin reveals a spherical architecture with a pheomelanin core and a eumelanin surface. 
  • Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. 
  • Time-dependent changes in the sensitivity of dopamine neurons to low doses of apomorphine following amphetamine infusion. 
  • Tyrosine hydroxylase mRNA in the neurons of the tuberoinfundibular region and zona incerta examined after gonadal steroid hormone treatment. 
  • Voltammetric evidence for discrete serotonin circuits, linked to specific reuptake domains, in the mouse medial prefrontal cortex. 
  • Working memory performance and cholinergic effects in the ventral tegmental area and substantia nigra. 
  • α-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration. 
• 

  Keywords of People

  • Johnson, G. Allan, Charles E. Putman University Distinguished Professor of Radiology, Physics
  • Turner, Dennis Alan, Professor of Neurosurgery, Biomedical Engineering